Previous 10 | Next 10 |
The Premium Portfolio has gained +44.54% YTD compared to the S&P 500 +14.81% YTD beating the index by +29.7% with one week to go. The Premium Portfolio has beaten the S&P 500 every year since inception with 32% avg annual returns from 20.8% in 2018, 30.7% in 2019. Weekly r...
Many of the best stocks in 2020 were healthcare companies focused on two disease areas: trying to stop the spread of COVID-19 and improving survival rates from deadly diseases. Their scientific achievements have been nothing less than extraordinary. By looking at healthcare companies with m...
Co-Diagnostics (CODX) sells over 10M of its Logix Smart COVID-19 Test Kits to its domestic and international network of laboratories, hospitals, and distributors.Company expects strong revenue in Q4 anticipated to exceed that of Q3.In addition to its Logix Smart COVID-19 test, the C...
Co-Diagnostics Announces Milestone of Over 10 Million COVID-19 Tests Sold SALT LAKE CITY , Dec. 14, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of mole...
Co-Diagnostics (NASDAQ: CODX) might be the strongest growth stock in the market right now, with third-quarter revenue up about 50,000%. This is a bit of a misleading statistic, as the company had only $41,000 in revenue at this time last year. Nonetheless, to drive sales from such a...
Shares of Co-Diagnostics (NASDAQ: CODX) were jumping 17.4% as of 3:09 p.m. EST on Wednesday. The gain came after the company announced that its joint venture, CoSara Diagnostics, received clearance in India to market the Saragene COVID-19 diagnostic test. Why are investors cheer...
Co-Diagnostics ([[CODX]] +15.5%) announces that CoSara Diagnostics, its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization in India to manufacture and sell its Saragene, Logix Smart SARS-CoV-2 (genes RdRp/E) multiplex ...
Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for COVID-19 2-Gene Multiplex Test PR Newswire SALT LAKE CITY, Nov. 25, 2020 SALT LAKE CITY , Nov. 25, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular di...
New York City, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The global upsurge in COVID-19 has kept testing and Co-Diagnostics (NASDAQ: CODX) under the analysts’ microscope. Within its client circular, the analyst from H.C. Wainwright & Co. predicted that Co-Diagnostics' Logix Sm...
FinancialBuzz.com News Commentary New York, NY (11/19/2020) – Recent reports from across the country clearly show that infection cases are once again surging. More than 11.4 million Americans have now been infected with the virus and the number of deaths has surpassed 248,000. In...
News, Short Squeeze, Breakout and More Instantly...
Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago PR Newswire SALT LAKE CITY , July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company wi...
Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast PR Newswire SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the developme...
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States PR Newswire SALT LAKE CITY , July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company w...